In a Sept. 4 research note, analyst Scott Henry reported ROTH Capital Partners expects Catalyst Pharmaceuticals Inc.'s (CPRX:NASDAQ) Firdapse has a 90% chance of getting regulatory approval as a treatment for Lambert-Eaton myasthenic syndrome (LEMS) at its upcoming PDUFA date, Nov. 28, 2018. ROTH's confidence is largely based on two factors, noted Henry. One is the strong clinical results Catalyst has demonstrated for Firdapse in LEMS to date. The other, which reduces regulatory risk, is the fact the FDA provided input on Catalyst's Phase 3 trial, including the design and endpoints along with the method for analyzing the resulting data. Also in the report, Henry relayed that ROTH revised some of its estimates pertaining to the likely impending launch of Firdapse (amifampridine phosphate), Catalyst's lead product candidate, for LEMS. The investment banking firm boosted its estimate of annual revenue from Firdapse to $185,000 per patient from $100,000 per patient.